1 The urinary excretion of sulphamethoxazole and its metabolites was compared between healthy volunteers and HIV-seropositive patients in order to get a better understanding of why HIV séropositives are more predisposed to idiosyncratic toxicity of sulphonamides. 2 A single 800 mg oral dose of sulphamethoxazole was administered to seven healthy volunteers and seven asymptomatic HIV séropositives without previous use of sulphonamides. 3 Urine was collected for 4 days and drug analysis was by h.p.l.c. 
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(SM X with seronegative individuals and oxidation [17] [18] . The latter reactions are cyto jstflsu i postulated chrome P450 mediated [19] and take place at the C5 hydroxylamine m etabolites o f sulphonam ides mediate carbon atom, leading to 5 -hydroxysulpham ethoxazole SMX) adverse reactions [11] [12] [13] , Toxicity is more likely to occur when the scavenging system for such reactive interm ediates is deficient, i.e. glutathione deficiency in HIV infection [14] [15] . In vitro studies metabolite SMX) »table and toxic hydroxylam ine SMX) [20] . Hydroxylam ines can have confirmed the relationship between increased undergo auto-oxidation to nitroso derivatives, a pro toxicity of hydroxylam ines towards lymphocytes of cess prevented by glutathione. HIV-infected individuals and decreased glutathione concentrations in these cells [16] .
known m etabolism ( Figure 1 ) methoxazole (SM X) involves acétylation leading to
We have previously reported the formation and elimination of SMX and all its known metabolites in healthy volunteers after administration of a single oral dose f21. 221. We now report a similar studv in 
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Sulphamethoxazole hydroxylamine Sulphamethoxazole HIV-seropositive individuals in order to obtain more Sampling procedures insight into the reasons why HIV séropositives are more predisposed to sulphonamide toxicity.
Blood samples were only from the
M ethods
Subjects volunteers while urine samples were collected from both healthy volunteers and séropositives. Blood sam ples were obtained by fingertip puncture at 1, 2, 4, 6 , 8 , 10, 12, 24, 32, 36, and 48 h after drug admin istration. Plasma was separated immediately by cen trifugation and stored at -2 0° C until analysis. Urine was collected over 96 h and three 5 ml aliquots were Seven healthy volunteers (4 M, 3 F) aged between 23 stored immediately at -20° C until analysis. and 50 years (mean 34 years) and seven HIV-seroSam ple treatment and drug analysis has been de positive volunteers participated in the study after scribed in detail elsewhere [18] . approval of the Ethics Com m ittee of Academ ic Hos pital, Nijmegen. Routine biochemical assessments D ata analysis (including liver function) were within normal limits in all participants. The HIV-seropositive individuals Curve fitting of the plasma concentration-and renal (6 M, 1 F) were aged between 31 and 53 years (mean excretion rate-time curves was carried out using a one 39 years), were all asymptomatic, CDC class II, had a mean CD 4 count of 294 ± 111/mm3 (range 140-480/ m m 3) and were without previous sulphonamide treatlated using the M edi-ware® computer program [23] .
com partm ent model with first order drug absorption ( r 2 < 0.98) and pharmacokinetic ment after seroconversion.
The following parameters for V4-SM X were calcu-W ritten inform ed consent was obtained from all lated from the renal excretion rate-time profiles: elimparticipants. An 800 mg dose of sulpham ethoxazole ination half-life (fi/2,y), lag time (t\a"), time at which was adm inistered orally in two gelatine capsules after m axim um excretion occurs (imax), mean an overnight fast. Two volunteers participated twice tim e (MRT = VSS/C L + \/ka + f|ag), maximal renal in the study in order to determine the reproducibility.
excretion rate (Umax) and area under renal excretion
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In addition, íi/2,z, flag, /max and MRT for N 4-SM X in olasma of healthv voi S M X volunteers.
Statistics
95% confidence intervals on the differences of the m eans for unpaired (or paired when appropriate) observations were determined.
Results
The urinary recoveries of parent drug and metabolites were similar in both HIV-negative and HIV-positive subjects with the exception of the urinary excretion o f N O H-SM X (see Table 1 ). T h e pharm acokinetic p a ra m e te rs of urine listed in Table 2 
